Clinical Trial

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.
Trial Details
NCT Number NCT06775275
Lead Sponsor The First Affiliated Hospital of Guangzhou Medical University
Conditions Resectable Lung Non-Small Cell Carcinoma
Enrollment 60 participants
Start Date 2024-09-24
Primary Completion 2025-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-15